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ing both new medical and psychological symptoms as they
age. However, there has been very little information written
about this phenomenon, although late onset medical prob-
lems have been documented, particularly in the Australian
Rubella population born in the 1940 s. The results of this
study are helpful in understanding both medical and psycho-
logical symptoms of the CRS adults, and anticipate potential
diseases and behaviors.
doi:10.1016/j.ijid.2010.02.649
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Inhibition of high risk HPV-31 in human cervical epithelial
cells in vitro by the PC-PLC inhibitor LMV-601
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Background: Expression of early genes and episomal DNA
replication of human papilloma virus (HPV) is dependent
from an active AP1 complex. Activation of AP1 was shown
to be precluded by inhibition of phosphatidylcholine spe-
ciﬁc phospholipase C (PC-PLC). We studied the effect of
the PC-PLC inhibitor LMV-601 on HPV-31 infected 9E cervical
epithelial cells (CIN 612 9E).
LMV-601 is (-)-exo/exo-O-Tricyclo-[5.2.1.0(2,6)]-dec-9-
yl-dithiocarbonate potassium salt. Tricyclo-[5.2.1.0(2,6)]-
dec-9-yl-dithiocarbonate potassium salt consists of 8
isomers (4 diastereomers, each having 2 enantiomers) and
became known under the code D609, ﬁrst synthesized in
1984 by Merz and Co in co-operation with the German Can-
cer Research Centre (DKFZ). The pure (-)-exo/exo isomer
was ﬁrst isolated in 2006 and is developed by Lumavita AG
as an antiviral drug.
Methods: 9E HPV-31 infected cervical epithelial cells
were from L.A. Laimins, Chicago.
(a) Short term study: After 72 h treatment, effect on cell
growth, HPV-31 speciﬁc DNA (Southern Blotting) and RNA
(Northern Blotting) was assessed.
(b) Long term treatment (9 passages): After each pas-
sage, viral RNA and DNA levels, and cell morphology were
assessed.
Results: (a) Short term study: LMV-601 displayed a dose
dependent inhibitory effect on cell growth(IC50 16 !g/mL),
HPV-31 speciﬁc RNA expression (IC50 10.69 !g/mL) and DNA
content (62.5% reduction at the highest dose tested, i.e. 32
!g/mL).
(b) Long term treatment: The number of passages
required to reduce the amount of HPV-31 speciﬁc RNA by
50% (T50RNA) was 2.23 at 3.3 !g/mL LMV-601 and < 1 at 10
!g/mL LMV-601. The corresponding T50DNA values were 3.28
and < 1, respectively.
After six passages the growth rate of the cells was
reduced and the morphology of the cells changed from the
spindle form to a normal phenotype. After passage 9, cells
were enlarged, became senescent (identiﬁed by expres-
sion of the senescence marker beta-gal), and ceased to
grow.
When human, non-HPV immortalized HaCat ker-
atinocytes were treated with the same concentrations of
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MV-601, neither cumulative inhibition of growth rate nor
nduction of senescence could be observed.
Conclusion: LMV-601 inhibits HPV-31 speciﬁc RNA expres-
ion and DNA replication. Furthermore, these results
upport the hypothesis that chronic treatment with LMV-601
‘cures’’ pre-cancerous 9E keratinocytes by elimination of
PV genomes.
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Background: In Herpes Zoster, the pain precedes der-
atome manifestation from 10—12 hours to 2—5 days even
o 10 days. Zosterian pain last, however it’s intermittent.
ur goal in this study is in highlighting the topographic vari-
ty of Zosterian pain and initial misdiagnose related with
t.
In this study we have included 202 cases of Herpes Zoster.
7 of the them were initially not identiﬁed as Herpes Zoster.
he group age was 19—78 years old, time period from
998—2009. 37 of them were HIV positive. In our cases pain
recedes exantematic manifestation from 18 to 68 hours.
Methods: The cases were assessed based on correlation
etween neurotics zosterian pain and initial nosology.
Results: According to pain location we distinguished
hese initial misdiagnoses:
ocation Diagnosis Number of cases
ead migraine 8
inusitis frontal 2
titis 2
phtalmitis 3
rthritis temporo — mandibular1
dontalgya 2
horax angina pectoris 3
ericarditis 2
leuritis 13
neumonia 11
bdomen abdominal colic 6
idney colic 4
epatic colic 4
holecystitis 2
ezenterial thrombosis 1
rchitis 2
pper extremites cervical racialgya5
ervical spondylarthrose 7
horax racialgya 6
capulo-humeral bursitis 2
ower extremites ischialgya 7
iscal hernia 1
ngiopathies 2
olymialgya rheumatica 1
oxo-femoral arthritis 2
Conclusion: 1) Zoster cases identiﬁed wrong initially were
8.02%.
